Moors & Cabot Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 91.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,000 shares of the biopharmaceutical company’s stock after selling 325,023 shares during the period. Moors & Cabot Inc.’s holdings in Pfizer were worth $31,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Pfizer by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 456,203,630 shares of the biopharmaceutical company’s stock valued at $17,864,934,000 after buying an additional 5,289,511 shares during the period. BlackRock Inc. boosted its position in shares of Pfizer by 0.3% during the 2nd quarter. BlackRock Inc. now owns 407,048,272 shares of the biopharmaceutical company’s stock worth $15,940,011,000 after purchasing an additional 1,314,302 shares during the period. State Street Corp boosted its position in shares of Pfizer by 1.3% during the 2nd quarter. State Street Corp now owns 278,568,311 shares of the biopharmaceutical company’s stock worth $10,908,735,000 after purchasing an additional 3,681,456 shares during the period. Geode Capital Management LLC boosted its position in shares of Pfizer by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 96,381,189 shares of the biopharmaceutical company’s stock worth $3,764,312,000 after purchasing an additional 2,233,072 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 7.9% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 54,593,374 shares of the biopharmaceutical company’s stock worth $2,137,877,000 after purchasing an additional 4,018,496 shares during the period. 64.88% of the stock is owned by institutional investors and hedge funds.
In other news, insider John D. Young sold 150,000 shares of the company’s stock in a transaction on Thursday, November 11th. The shares were sold at an average price of $50.06, for a total value of $7,509,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Douglas M. Lankler sold 40,000 shares of the company’s stock in a transaction on Friday, November 26th. The shares were sold at an average price of $54.37, for a total transaction of $2,174,800.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 231,360 shares of company stock valued at $11,927,994. 0.05% of the stock is owned by insiders.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.08 by $0.26. Pfizer had a net margin of 27.66% and a return on equity of 30.70%. The firm had revenue of $24.09 billion during the quarter, compared to analyst estimates of $22.82 billion. During the same quarter in the prior year, the business posted $0.72 earnings per share. Pfizer’s revenue for the quarter was up 134.4% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 4.18 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 4th. Shareholders of record on Friday, January 28th will be paid a dividend of $0.40 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.91%. The ex-dividend date of this dividend is Thursday, January 27th. Pfizer’s payout ratio is currently 46.43%.
PFE has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “strong-buy” rating and set a $65.00 price objective for the company in a research report on Tuesday, January 4th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pfizer in a research report on Friday, November 5th. Mizuho increased their target price on shares of Pfizer from $44.00 to $56.00 and gave the stock a “neutral” rating in a report on Tuesday, December 14th. Barclays set a $54.00 target price on shares of Pfizer in a report on Tuesday. Finally, JPMorgan Chase & Co. set a $53.00 target price on shares of Pfizer in a report on Monday, December 13th. Nine equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Buy” and an average target price of $57.81.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
See Also: G-20
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.